Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
About Health Canada
Access to Information Requests Completed - April 2015
The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)
If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.
| Request # | Summary of Requests | Status of Completed Request | Number of Pages Disclosed |
|---|---|---|---|
| A-2013-00483 | Information related to the annual cost for all health services provided to Manitoba through the First Nations and Inuit Health Branch funding (Apr. 1, 1998 to July 31, 2013) | All disclosed | 2 |
| A-2013-01113 | Information on the number of complaints concerning electronic cigarettes received by Health Canada and adverse reaction reports (Jan. 1, 2009 to Dec. 16, 2013) | Disclosed in part | 481 |
| A-2014-00531 | Adverse Reaction Report (AER) for Creon. Report number: 000584748. | Disclosed in part | 15 |
| A-2014-00684 | Any records related to the medical marihuana about concerns HC heard from law enforcement officials, fire departments, and municipal officers across the country | Disclosed in part | 855 |
| A-2014-00703 | Information regarding the medical device # 1256 and #1251S (class II), License number #62 by Benlan Inc. | Disclosed in part | 13 |
| A-2014-00770 | Information on penalties imposed as a result of audits/inspections of each pharmaceutical company and by category: number of incidents, number of recalls and associated risk types (I, II, III) for January 1, 2006, to September 30, 2014. | All disclosed | 207 |
| A-2014-00907 | Adverse Reaction Report (AER) for Flagyl (metronidazole). Report number: 000577502. | Disclosed in part | 5 |
| A-2014-00910 | Adverse Reaction Report (AER) for Plaquenil (hydroxychloroquine sulfate). Report number: 000528307. | Disclosed in part | 15 |
| A-2014-00914 | Adverse Reaction Report (AER) for Flagyl (metronidazole). Report number: 000591575. | Disclosed in part | 23 |
| A-2014-00926 | Adverse Reaction Report (AER) for Plaquenil (hydroxychloroquine sulfate). Report numbers: E2B_00044145, 000541170, 000533724 and 000577851 | Disclosed in part | 44 |
| A-2014-00933 | Adverse Reaction Report (AER) for Glucophage (metformin hydrochloride). Report number: 000553046. | Disclosed in part | 4 |
| A-2014-00934 | Adverse Reaction Report (AER) for Demerol (pethidine hydrochloride). Report number: 000551327. | Disclosed in part | 2 |
| A-2014-00935 | Adverse Reaction Report (AER) for Demerol (pethidine hydrochloride). Report number: 000551327. | Disclosed in part | 6 |
| A-2014-00945 | Adverse Reaction Report (AER) for ULORIC (febuxostat). Report numbers: 000583638, 000595647 and 000601655. | Disclosed in part | 7 |
| A-2014-00952 | Adverse Reaction Report (AER) for NORVIR. Report numbers: 000606212, E2B_00089567, 000606214 and E2B_00090618. | Disclosed in part | 23 |
| A-2014-00968 | Adverse Reaction Report (AER) for Demerol (pethidine hydrochloride). Report number: 000530677. | Disclosed in part | 2 |
| A-2014-00995 | Adverse Reaction Report (AER) for Sodium Iodide I131. Report number: 000339733. | Disclosed in part | 1 |
| A-2014-01011 | Documents under the Marihuana for Medical Purposes Regulations (MMPR) covering authorized producers: policies or procedures for processing applications; advertising restrictions; application processing timelines; schedule for granting authorizations or the maximum or anticipated number; inspection regulations or procedures; processing of security authorization applications; rejection of applications (Jan. 1, 2014, to Nov. 15, 2014) | Disclosed in part | 163 |
| A-2014-01062 | Adverse Reaction Report (AER) for Fludara (fludarabine phosphate). Report number: E2B_00091011. | All disclosed | 8 |
| A-2014-01082 | Records which capture or estimate any costs incurred by the federal government's representations pertaining to the case ALLARD v. Her Majesty the Queen in Right of Canada and all of its proceedings to date, from the onset of the case in March 2014 up until and including the most recent court date of November 24, 2014 |
No records exist | 0 |
| A-2014-01114 | Documents from the Sioux Lookout First Nations Authority related to the number of audited annual financial statements for fiscal years 2011 to 2014 inclusive. | All disclosed | 29 |
| A-2014-01174 | Copies of the following briefing materials provided to the Deputy Minister and listed by Ministerial Executive Correspondence System number:
|
All disclosed | 13 |
| A-2014-01221 | Adverse Reaction Report (AER) for the following products/report numbers: Pantoloc (pantoprazole sodium) (000617889, 000620549, 000626749, 000627744, E2B_00142126), Tecta (pantoprazole magnesium) (000614580, 000619309, 000619631, 000620353, 000621924, 000624695, 000626742), Uloric (febuxostat) (000623943, 000627327, 000627154, | Disclosed in part | 43 |
| A-2014-01222 | Adverse Reaction Report (AER) for the following products/report numbers: Actos (pioglitazone) (000620486, 000617762), Alvesco (ciclesonide) (000615139, 000625145, E2B_00129652, E2B_00131206), Daxas (roflumilast) (000618305, 000624751, 000624981, 000627003, 000627384), Dexilant (dexlansoprazole) (000614420, 000615391, 000620844, 000623991, 000624750, 000624933, 000625761). | Disclosed in part | 68 |
| A-2014-01231 | Listing of the province, city and postal codes of all holders of an Authorization to Possess (ATP) licence under the Marihuana Medical Access Regulations (MMAR) program. | Disclosed in part | 662 |
| A-2014-01284 | Adverse Reaction Report (AER) for Rythmol. Report number: E2B_00144071. |
All disclosed | 16 |
| A-2014-01302 | Adverse Reaction Report (AER) for Isoflurane. Report number: E2B_00121963. | All disclosed | 15 |
| A-2014-01305 | Adverse Reaction Report (AER) for Humira. Report numbers: E2B_00127783; E2B_00118762; and E2B_00127176. | All disclosed | 26 |
| A-2014-01312 | Adverse Reaction Report (AER) 000624854. | Disclosed in part | 4 |
| A-2014-01313 | Adverse Reaction Report (AER) 000625386. | Disclosed in part | 2 |
| A-2014-01346 | Copies of the following briefing materials listed by Ministerial Executive Correspondence System numbers:
|
Disclosed in part | 18 |
| A-2014-01349 | Copy of the most recent list of constituents and emissions produced by tobacco companies. | No records exist | 0 |
| A-2014-01364 | All call-ups or contracts issued under the terms of the TBIPS Standing Offer and Supply Arrangement between the months of January 2014 to February 2014 and August 2014 to December 2014. | Disclosed in part | 1,448 |
| A-2014-01390 | Correspondence from the Parliamentary Secretary, Eve Adams, or her staff, regarding the Canadian Olympic Committee, the Olympics or government support for sports (May 2, 2011 to Feb 16, 2015) | No records exist | 0 |
| A-2014-01392 | Correspondence from the Member of Parliament, Eve Adams, or her staff, regarding Dimitri Soudas, Stampede Group or GTK Group (May 2, 2011 to Feb 16, 2015) | No records exist | 0 |
| A-2014-01398 | Copy of the Summary Basis of Decision and any supporting documents related to the approval of Ferriprox (deferiprone) by Health Canada | No records exist | 0 |
| A-2014-01399 | Information regarding the number of applications submitted, declined with notice, declined without notice and who made the final decision to decline the applications, under the Marihuana Medical Access Regulations program. | All disclosed | 1 |
| A-2014-01409 | Documents of all records of notification of health impairment and/or health effects submitted by the equipment owner the Canadian Auto Workers (CAW) and/or Unifor and by the manufacturer Enercon and its related entities for CAW wind turbine project in Port Elgin, Ontario (Mar. 25, 2013 to Feb. 16, 2015) | No records exist | 0 |
| A-2014-01476 | Labelling documents regarding ABILIFY MAINTENA (Aripiprazole), Drug Identification Numbers (DIN) 02420864 and DIN 02420872. | No records exist | 0 |
| A-2014-01485 | Information regarding the product "Move Free Advanced" (also "Move Free Advanced Triple Strength", marketed by Reckitt Benckiser (Canada) Inc. and its related literature case reports. | Disclosed in part | 16 |
| A-2014-01491 | Data in percentage and counts of the Canadian population smoking habits, by smoking status, quit attempts, smoke behaviour, education, age group (15+) and sex (1960 to 2014) | No records exist | 0 |
| A-2014-01498 | List of all companies that have received a Letter to Build or Permission to Proceed under the Marihuana for Medical Purposes Regulations (MMPR) | Disclosed in part | 1 |
| A-2014-01509 | List of all the studies conducted by the Applied Research and Analysis Directorate (Apr. 1, 2014 to Mar. 28, 2015) | All disclosed | 1 |
| A-2014-01513 | Adverse Reaction Report (AER) for Lovenox (enoxaparin sodium). Report number: 000617464. | Disclosed in part | 1 |
| A-2014-01514 | Adverse Reaction Report (AER) for Plavix (clopidogrel bisulphate). Report number: 000614678. | Disclosed in part | 1 |
| A-2014-01544 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, any briefing notes for the Minister related to the March 2015 Department-Victims meetings, whether prepared before or after the meetings | No records exist | 0 |
| A-2014-01545 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, any briefing notes for the Deputy Minister or Associate Deputy Minister related to the March 2015 Department-Victims meetings, whether prepared before or after the meetings | No records exist | 0 |
| A-2014-01554 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, copies of communications received by the Department, excluding communications received from the victims and their organizations, the victim advocates, officials of other departments, media and researchers. (Jan. 2, 2012 to Dec. 31, 2014) | No records exist | 0 |
| A-2014-01555 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, copies of communications related to Thalidomide received by the Department, excluding communications received from the victims and their organizations, the victim advocates, other Government of Canada officials, officials of other governments, media and researchers. (Jan. 1, 2015 and Mar, 25, 2015) | No records exist | 0 |
| A-2014-01556 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, any briefing note prepared for the Minister on Motion M-546 of Ms. Libby Davis placed on Nov. 24, 2014 and withdrawn on Dec 10, 2014, or on the Opposition Motion on Survivors of Thalidomide of Ms. Davies placed on notice November 25, debated November 27 and adopted by the House of Commons on December 1, 2014 | No records exist | 0 |
| A-2014-01558 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, any briefing notes prepared for the Parliamentary Secretary to the Minister on Motion M-546 or on the Opposition Motion on Survivors of Thalidomide | No records exist | 0 |
| A-2014-01559 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, any briefing notes prepared for the Deputy Minister or Associate Deputy Minister on Motion M-546 or on the Opposition Motion on Survivors of Thalidomide | No records exist | 0 |
| A-2014-01563 | With reference to the March 5, 2015 announcement of a financial assistance package for Canadian survivors of Thalidomide, any other briefing notes related to Thalidomide prepared for the Minister, Deputy Minister or Associate Minister in 2013 | No records exist | 0 |
